- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Follow-up on Patient With Pseudopseudohypoparathyroidism
Two years ago, Dr Alexander K. C. Leung reported on a case of pseudopseudohypoparathyroidism. The patient was a 13-year-old girl with short stature, short fourth metacarpals and metatarsals, mild mental retardation, and no identifiable biochemical abnormalities.
Two years ago, Dr Alexander K. C. Leung reported on a case of pseudopseudohypoparathyroidism (CONSULTANT, April 1999, page 1296). The patient was a 13-year-old girl with short stature, short fourth metacarpals and metatarsals, mild mental retardation, and no identifiable biochemical abnormalities (A).
Drs Leung and Justine H. S. Fong of Calgary, Alberta, report that this patient, now 15 years old, presented with pain and swelling of the right fourth finger of 3 months' duration. Restriction of movement was noted in the digit's distal interphalangeal joint. A radiograph of the right hand showed a short fourth metacarpal and extensive metastatic calcification on the posterolateral margin of the distal and middle phalanges of the middle finger (B). The area of calcification measured approximately 1 × 3.5 cm.
Metastatic calcification in patients with pseudopseudohypoparathyroidism commonly affects the subcutaneous tissues and basal ganglia.
Sotagliflozin in Patients with Type 1 Diabetes and CKD to be Discussed at October FDA AdComm Meeting
October 14th 2024Lexicon's sotagliflozin is on the October 31 docket for discussion by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee; PDUFA goal date remains set for December 20.
